There are currently 2030 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
NCT06171685
Recruiting
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready and whether accrual in the trial will support another arm. Accrual to an arm will terminate in accord with the arm's appendix to the Master Protocol. The purpose of this proposed s... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/10/2025
Locations: University of Chicago Cancer Center, Chicago, Illinois
Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors
NCT06555952
Recruiting
Inflammation and stressors can interfere with the function of the lining of blood vessels and insulin activity, therefore, investigators are aiming to see how the Grape seed Extract (GSE) called MegaNatural BP can help with limiting the effects of these factors. This research will study the effects of taking 150mg of MegaNatural BP GSE per day on blood pressure levels along with influences on heart health through assessing the function of the blood vessel lining and levels of inflammation.
Gender:
ALL
Ages:
Between 40 years and 60 years
Trial Updated:
07/10/2025
Locations: Clinical Nutrition Research Center, Chicago, Illinois
Conditions: Hypertension, Pre Diabetes
Register for Updates
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
NCT06941844
Recruiting
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
07/10/2025
Locations: Uptown Research, Chicago, Illinois
Conditions: Major Depressive Disorder
Register for Updates
Optimizing Mango's Glycemic Impact: Investigating Mango Consumption Timing in Prediabetic Individuals
NCT06986161
Recruiting
The purpose of this study is to investigate the effect of mango intake on metabolic and inflammatory responses relative to meals in individuals at risk of developing diabetes, as well as to understand how the beneficial compounds found in mangoes are absorbed and processed in the body.
Gender:
ALL
Ages:
Between 20 years and 60 years
Trial Updated:
07/10/2025
Locations: Clinical Nutrition Research Center, Chicago, Illinois
Conditions: Pre Diabetes
Register for Updates
Characterization of Human Olfactory Amygdala Subregions Exp3
NCT07060651
Recruiting
We aim to better understand the functions of the subregions of the human amygdala that receive direct projections from the olfactory bulb
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Northwestern human olfaction lab, Chicago, Illinois
Conditions: Human Olfactory Amygdala Function
Register for Updates
Characterization of Human Olfactory Amygdala Subregions exp2
NCT07074574
Recruiting
We aim to better understand the functions of the subregions of the human amygdala that receive direct projections from the olfactory bulb
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Northwestern human olfaction lab, Chicago, Illinois
Conditions: Changes in Olfactory Behavior Across Different Contexts Associated With Different Amygdala Subregions
Register for Updates
Nutrition for Precision Health, Powered by the All of Us
NCT05701657
Recruiting
The goal of this investigational study is to develop algorithms that predict human response to foods. The main question it aims to answer are: * How does varying foods and eating patterns impact one's biological and physiological responses? * In what ways can novel dietary assessment measures be used to improve dietary assessments and to prescribe assessments to people in future research with increased precision? * Can artificial intelligence and machine learning techniques be combined to presc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Northwestern University, Chicago, Illinois +2 locations
Conditions: Nutrition, Health, Dietary Habits
Register for Updates
Case Management Dyad
NCT06162897
Recruiting
The overall goal of this study is to test whether dyadic and focused case management will (1) improve financial wellbeing, (2) improve access to food, (3) increase linkage and retention rates for individuals living with HIV or those taking PrEP (PrEP persistence), and (4) increase the proportion of individuals living with HIV who are virally suppressed (viral suppression) when compared to routine Ryan White Non-Medical Case Management.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: HIV, Pre-exposure Prophylaxis, Case Management
Register for Updates
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
NCT06441890
Recruiting
Adult men and women with early-stage, IHC/FISH-defined HER2-positive breast cancer will have a MammaPrint®/BluePrint® assay performed on the diagnostic biopsy specimen, ordered by the treating Oncologist as standard care
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: University of Illinois, Chicago, Illinois
Conditions: Breast Cancer, HER2-positive Breast Cancer
Register for Updates
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
NCT06465953
Recruiting
This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previously. Participants will be randomized to receive either ivosidenib (IVO) alone or azacitidine (AZA) alone. IVO will be administered daily throughout the 28-day treatment cycle and AZA will be administered for the first 7 days of each 28-day cycle. Study visits will be conducted every week during Cy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: University of Chicago, Duchossois Center for Advanced Medicine (DCAM), Chicago, Illinois
Conditions: Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
Register for Updates
Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
NCT06498960
Recruiting
Prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/09/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Normal Pressure Hydrocephalus
Register for Updates
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844
Recruiting
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Research Site, Chicago, Illinois
Conditions: Non-small Cell Lung Cancer
Register for Updates